دورية أكاديمية
أعرض في EDS

COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision.

التفاصيل البيبلوغرافية
العنوان: COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision.
المؤلفون: San Segundo D; Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Transplantation and Autoimmunity Laboratory, Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain., Comins-Boo A; Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain., Lamadrid-Perojo P; Transplantation and Autoimmunity Laboratory, Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain., Irure-Ventura J; Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Transplantation and Autoimmunity Laboratory, Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain., Castillo-Otí JM; Epidemiological Monitoring and Intervention Unit of Liencres Hospital, 39120 Piélagos, Spain.; Comunitary Health Group Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain.; Nursing Department, School of Nursing, University of Cantabria, 39008 Santander, Spain., Wallman R; Department of Public Health, Cantabrian Government, 39008 Cantabria, Spain., Calvo-Montes J; Microbiology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Epidemiology and Molecular and Pathogenic Mechanisms of Infectious Diseases and Clinical Microbiology Group Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain., Méndez-Legaza JM; Microbiology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Epidemiology and Molecular and Pathogenic Mechanisms of Infectious Diseases and Clinical Microbiology Group Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain., Baamonde-Calzada C; Clinical Analysis Department, Sierrallana Hospital, 39300 Torrelavega, Spain., Sánchez-Molina I; Clinical Analysis Department, Laredo Hospital, 39770 Laredo, Spain., Lecue-Martínez M; Epidemiological Monitoring and Intervention Unit of Liencres Hospital, 39120 Piélagos, Spain., Ventisca-Pérez S; Epidemiological Monitoring and Intervention Unit of Liencres Hospital, 39120 Piélagos, Spain., Batlle-López A; Haematology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Haematologic Neoplasms and Haematopoietic Stem Cells Transplantation, IDIVAL, 39008 Santander, Spain.; Laboratory Informatic Management System Coordinator (LISCAN), Servicio Cantabro de Salud (SCS), Consejeria de Sanidad, 39008 Cantabria, Spain., Hoyos ML; Immunology Department, University Hospital Marqués de Valdecilla, 39008 Santander, Spain.; Transplantation and Autoimmunity Laboratory, Research Institute 'Marqués de Valdecilla' (IDIVAL), 39008 Santander, Spain.; Molecular Biology Department, University of Cantabria, 39011 Santander, Spain.
المصدر: Vaccines [Vaccines (Basel)] 2021 Dec 02; Vol. 9 (12). Date of Electronic Publication: 2021 Dec 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Nursing home residents (NHR) have been targeted as a vaccination priority due to their higher risk of worse outcome after COVID-19 infection. The mRNA-based vaccine BTN2b2 was first approved in Europe for NHRs. The assessment of the specific vaccine immune response (both humoral and cellular) at long term in NHRs has not been addressed yet. A representative sample of 624 NHR subjects in Northern region of Spain was studied to assess immune response against full vaccination with BTN2b2. The anti-S1 antibody levels and specific T cells were measured at two and six months after vaccination. 24.4% of NHR had a previous infection prior to vaccination. The remaining NHR were included in the full vaccination assessment group (FVA). After two months, a 94.9% of the FVA presented anti-S1 antibodies, whereas those seronegative without specific cellular response were 2.54%. At long-term, the frequency of NHR within the FVA group with anti-S1 antibodies at six months were 88.12% and the seronegative subjects without specific cellular response was 8.07%. The cellular immune assays complement the humoral test in the immune vaccine response assessment. Therefore, the cellular immune assessment in NHRs allows for the fine tuning of those seronegative subjects with potential competent immune responses against the vaccine.
References: MMWR Morb Mortal Wkly Rep. 2020 Dec 11;69(49):1857-1859. (PMID: 33301429)
Allergy. 2022 Jan;77(1):271-281. (PMID: 34286856)
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072. (PMID: 33906236)
J Am Med Dir Assoc. 2021 Sep;22(9):1853-1855.e1. (PMID: 34375655)
Am J Transplant. 2021 Aug;21(8):2727-2739. (PMID: 34036720)
Nature. 2021 Apr;592(7855):616-622. (PMID: 33567448)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
Am J Transplant. 2021 Dec;21(12):3971-3979. (PMID: 34291552)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Nature. 2021 Aug;596(7872):417-422. (PMID: 34192737)
Blood Cancer J. 2021 Aug 10;11(8):142. (PMID: 34376633)
Euro Surveill. 2021 Jun;26(24):. (PMID: 34142647)
Lancet Healthy Longev. 2021 Sep;2(9):e544-e553. (PMID: 34430954)
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):52-55. (PMID: 33444301)
Nat Med. 2021 Jun;27(6):981-984. (PMID: 33795870)
J Clin Invest. 2020 Dec 1;130(12):6728-6738. (PMID: 32910806)
Immunol Res. 2021 Dec;69(6):576-583. (PMID: 34417958)
Vaccines (Basel). 2021 Jun 10;9(6):. (PMID: 34200835)
Eur Geriatr Med. 2020 Dec;11(6):899-913. (PMID: 33141405)
Biomedicines. 2021 Jul 22;9(8):. (PMID: 34440072)
Lancet Healthy Longev. 2021 Sep;2(9):e554-e560. (PMID: 34401865)
معلومات مُعتمدة: 2020 UIC22-PUB-0019 Cantabrian Government
فهرسة مساهمة: Keywords: SARS-CoV-2; cellular-immune response; mRNA vaccine; nursing home residents; public health
تواريخ الأحداث: Date Created: 20211228 Latest Revision: 20211231
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8703754
DOI: 10.3390/vaccines9121429
PMID: 34960173
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines9121429